Abstract The purpose of this study is to examine the breast cancer risk overall among women with simple fibroadenoma or complex fibroadenoma and to examine the association of complex fibroadenoma with breast cancer through stratification of other breast cancer risks. The study included women aged 18-85 years from the Mayo Clinic Benign Breast Disease Cohort who underwent excisional breast biopsy from 1967 through 1991. Within this cohort, women who had fibroadenoma were compared to women who did not have fibroadenoma. Breast cancer risk (observed versus expected) across fibroadenoma levels was assessed through standardized incidence ratios (SIRs) by using age-and calendar-stratified incidence rates from the Iowa Surveillance, Epidemiology, and End Results registry. Analyses were performed overall, within subgroups of involution status, with other demographic characteristics (age, year of biopsy, indication for biopsy, and family history), and with histologic characteristics, including overall impression [nonproliferative disease, proliferative disease without atypia (PDWA), or atypical hyperplasia]. Fibroadenoma was identified in 2136 women [noncomplex, 1835 (85.9 %); complex, 301 (14.1 %)]. SIR for noncomplex fibroadenoma was 1.49 (95 % CI 1.26-1.74); for complex fibroadenoma, it was 2.27 (95 % CI 1.63-3.10) (test for heterogeneity in SIR, P = .02). However, women with complex fibroadenoma were more likely to have other, concomitant high-risk histologic characteristics (e.g., incomplete involution and PDWA). In analyses stratified by involution status and PDWA, complex fibroadenoma was not an independent risk marker for breast cancer. Complex fibroadenoma does not confer increased breast cancer risk beyond other established histologic characteristics.
Introduction
Fibroadenoma (FA) is a benign breast lesion that occurs most commonly in premenopausal women, but it can occur in women at any age [1] . Several reports have described a higher risk of subsequent breast carcinoma among patients who have FA, with relative risks (RRs) ranging from 1.48 to 1.7 [1] [2] [3] [4] [5] . At the tissue level, FA is a benign tumor composed of both epithelial and stromal components. Complex FAs are FAs with associated histologic characteristics, including cysts (C3 mm), sclerosing adenosis, epithelial calcifications, or papillary apocrine metaplasia [2] . A prior report from Dupont et al. [2] showed that the RR of invasive breast cancer (BC) was 2.17 times higher for patients with FA than for matched controls (95 % CI 1.5-3.2). The RR increased to 3.10 for women with complex FAs (95 % CI 1.9-5.1) and remained elevated for more than 20 years after diagnosis [2] . Further increases in risk were reported for patients with FA who had (1) benign proliferative disease without atypia (PDWA) in the surrounding parenchyma adjacent to the FA (RR 3.47; 95 % CI 1.8-6.8), (2) atypical hyperplasia in the surrounding parenchyma (RR 7.29; 95 % CI 2.2-24), and (3) a family history of BC (RR 3.72; 95 % CI 1.4-10) [2] .
Currently, FA is diagnosed when a patient presents with a palpable lump or has a breast imaging procedure that shows an abnormality that is investigated with percutaneous biopsy. Because FA is a benign finding, most patients with FA are subsequently followed by their primary care providers. Hence, the risk association of FA with BC, and by type of FA (complex or simple), should be clarified so that women with FA can be appropriately counseled about future screening and risk reduction strategies.
In the present study, we investigated the BC risk associated with FA, both overall and stratified into complex and simple FA. In addition, we evaluated the associations stratified by individual histologic criteria (i.e., cysts C3 mm, sclerosing adenosis, epithelial calcifications, and papillary apocrine metaplasia) to clarify whether a specific feature of complex FA was more closely associated with risk. Lastly, we evaluated the effect of proliferative disease and atypical hyperplasia (within FA or adjacent to FA, or both) to further stratify risk.
Methods

Study population
The study was conducted with the Mayo Clinic benign breast disease (BBD) cohort [6, 7] . The characteristics of the patients, the inclusion and exclusion criteria, and the assessment of the pathologic specimens have been described extensively in earlier reports [6, 7] . Briefly, the study population consisted of 9076 women aged 18-85 years who underwent surgical excision of a benign breast lesion at Mayo Clinic in Rochester, Minnesota, from January 1, 1967, through December 31, 1991. Details about family history of BC and subsequent BC events were obtained from medical records and questionnaires sent to patients and next of kin. Family history of BC was classified as negative (if there was no family history of BC); strong (if there was C1 first-degree relative with BC before age 50 years or C2 relatives with BC, with C1 being a firstdegree relative); or weak (for any family history not classified as strong).
Histologic examination
If the woman had more than 1 biopsy during the study period, we used findings from the earliest biopsy performed. For each participant, stored hematoxylin-eosinstained sections were evaluated by an experienced breast pathologist (D.W.V.). The biopsy findings were classified according to the criteria proposed by Page and Anderson [8] as nonproliferative disease, PDWA, or atypical hyperplasia (AH) (including atypical ductal hyperplasia or atypical lobular hyperplasia, or both). PDWA criteria were ductal hyperplasia (more than mild), papillomas, radial scar, or sclerosing adenosis (C2 foci of lobular units involved and C1 focus with a diameter larger than that of a normal lobule). Other histologic features, such as cysts, apocrine metaplasia, FA, sclerosing adenosis (\2 lobular units involved), or columnar cell changes, were considered to be nonproliferative unless they also contained 1 of the described proliferative lesions. Sufficient tissue was available to assess the presence or absence of FA for the 9076 women. FA was diagnosed when a fibroepithelial lesion with both ductal epithelial and stromal fibrous proliferations measured at least 4.0 mm in diameter [9] . Another breast pathologist (A.N.) carried out a second review of all cases with FA and categorized the parenchyma as either PDWA or AH.
At secondary review, all FAs were classified as complex or noncomplex. According to previously published criteria [8] , FA was classified as complex ( Fig. 1) when it contained 1 or more of the following: cyst diameter 3 mm or larger, sclerosing adenosis, epithelial calcifications, and papillary apocrine metaplasia. In addition, other coexisting histologic findings were recorded for each biopsy sample: nonproliferative and proliferative lesions (as described above), and AH. Each sample was evaluated for the presence of surrounding breast parenchyma adjacent to the FA and was defined as sufficient for evaluation if it was at least 0.5 cm 2 in area or if it had five lobular units (a lobular unit is a cluster of acini that drain into a terminal duct lobular unit). Finally, the location of all PDWA and AH findings was documented (as within the FA, in adjacent parenchyma, or in both locations).
The adjacent breast parenchymal tissue was also evaluated for extent of lobular involution. Lobular involution was classified as no involution (0 % involuted lobules), partial involution (1-74 % involuted lobules), or complete involution (C75 % involuted lobules) [7] .
The Mayo Clinic Institutional Review Board approved the research. Informed consent was also received from all participants.
Statistical analysis
Data were summarized descriptively as frequencies and percentages for categorical variables and as means and ranges for continuous variables. We used v 2 tests of significance to compare the presence of FA across the levels of categorical variables (including age at biopsy, era of biopsy, indication for biopsy, histologic impression, extent of lobular involution, and family history of BC).
Duration of follow-up was calculated as the number of days after biopsy of a benign lesion to the date of BC diagnosis, death, or last contact. In addition, if women had prophylactic mastectomies or a diagnosis of lobular carcinoma in situ, their data were censored at the date of such an occurrence. Standardized incidence ratios (SIRs) with 95 % CIs were used to estimate RRs; SIRs were calculated by dividing the actual number of women who had BC by the number expected to have BC. The expected number was determined by dividing the patient's follow-up into 5-year periods according to the patient's age and according to the calendar period; this accounted for differences related to the variables. The reference population was the Iowa surveillance, epidemiology, and end results registry [6] . Like the Mayo Clinic patients, 80 % of the reference population lived in the Upper Midwest, and the two groups were similar demographically (e.g., [95 % of both groups were white) [6] . SIRs were calculated for the overall group and for subgroups defined by histologic impression and other BBD characteristics. Potential heterogeneity in SIRs across subgroups was assessed with Poisson regression analysis; the offset term was the log-transformed expected event rate for each patient. All statistical analyses were 2-sided and used SAS statistical software (SAS Institute Inc). P values less than .05 were considered statistically significant.
Results
Clinicopathologic characteristics
A total of 9076 women comprised the cohort: 6940 (76.5 %) with no FA; 1835 (20.2 %) with simple FA; and 301 (3.3 %) with complex FA. Mean age was 52.2 years for women without FA, 45.8 years for women with simple FA, and 50.2 years for women with complex FA. Nearly half the women with simple FA were younger than 45 years, compared with 40 % for women with complex FA (Table 1) .
Simple FA was detected more often as a lump (57.2 %) compared to complex FA (49.0 %). Complex FA was more common in the post-mammographic era between 1982 and 1991 (65.8 %) compared to the pre-mammographic era before 1982 (34.2 %). The proportion of women with FA who also had AH was low overall but approximately four times greater in the complex FA group (6.0 %) than in the simple FA group (1.6 %).
Involution differed among women according to FA status, with a general trend toward less complete involution in women with FA compared to those without. Complete involution was seen less frequently in women with simple FA (n = 216; 15.1 %) and complex FA (n = 27; 11.7 %) than in women without FA (n = 1588; 23.3 %) (P = .002). Family history of BC was not common among women with either simple FA or complex FA. Strong family history was noted for only small percentages of women with simple FA (8.7 %) or complex FA (11.7 %). (Table 2) . However, women with simple FA presenting with a breast lump (RR 1.95; 95 % CI 1.59-2.38) had a higher risk than those with FA detected on mammography (RR 1.09; 95 % CI 0.80-1.44; P \ .001).
As expected, there was a significant difference in risk when simple FA was associated with proliferative disease compared to nonproliferative disease (RR 1.20; 95 % CI 0.97-1.45), PDWA (RR 2.73; 95 % CI 1.99-3.66), or AH (RR 4.07; 95 % CI 1.49-8.86; P \ .001) ( Table 2 ). Similar trends were seen for women with complex FA, but results were not statistically significant, in part because the sample sizes were smaller (test for heterogeneity in RR between simple FA and complex FA: P = .35 for NP, P = .32 for PDWA, and P = .59 for AH). For women with proliferative disease, the location of proliferative histologic findings Test for heterogeneity in risk of breast cancer across levels of attribute in association with FA was also studied ( Table 3 ). The BC risk was not different when the PDWA was located adjacent to the FA or within the FA (P = .97). Similarly, the risk was not influenced by the location of AH, whether adjacent to or within the FA (P = .41). Findings were similar when we looked at simple and complex FA separately, although the numbers in each category were too small in the subgroup analysis. Of the 4 proliferative disease components of FA, sclerosing adenosis was predominant (79.4 %; 239 of 301). No individual component conferred an increased risk of BC compared to the others (Table 4) , although these analyses were limited by power and should be interpreted with caution. The presence of any 1 of the histologic criteria was not associated with increased risk of BC, but when 2 (RR 2.67; 95 % CI 1.52-4.33) or more (RR 7.77; 95 % CI 3.13-15.99) histologic features of complex FA were found simultaneously in the complex FA, there was an increase in BC risk. However, the group of women with three lesions in a complex FA was very small (6.3 %; 19 of 301) ( Table 4) . However, in analyses stratified by histologic impression, these differences attenuated greatly, suggesting that the risk of BC with FA was associated with the greatest degree of epithelial proliferation (PDWA or AH, whether within or adjacent to the FA) rather than with the mere presence of FA. Dupont et al. [2] described BC risk in women with FAs almost two decades ago. In a retrospective cohort study of 1835 women with FA biopsied from 1950 through 1968, BC developed in 87 (4.7 %). In a comparison with two control groups, one of which included the patient's sister-in-law, Dupont et al. concluded that FA confers an overall RR of 2.17 (95 % CI 1.5-3.2). However, this risk increased to 3.10 (95 % CI 1.9-5.1) for 422 women with complex FA, including 29 (6.9 %) who had BC. Dupont et al. [2] further showed that this increased risk persisted for decades after the initial diagnosis. In the present study, 2136 women with FAs were studied and BC developed in 191 women (8.9 %) during a 20-year follow-up. The BC risk was slightly elevated for women with FA and more so for women with complex FA. Similar to the study findings of Dupont et al., although women with complex FA were at slightly elevated BC risk, the risk was not significantly different between women with simple FA and women with no FA (Table 2 ). It is notable that these two cohorts are among the largest cohorts of women with FA studied to date.
In the present study, among women with FA, the presence of PDWA or AH was associated with greater BC risk compared to nonproliferative disease (P \ .001) ( Table 2) . PDWA (including usual ductal hyperplasia other than mild, sclerosing adenosis, papillomas, and radial scar) was noted in 22.9 % (490 of 2136) of all women with FA and more frequently in women with complex FA (218 of 301; 72.4 %). In comparison, Dupont et al. [2] reported an incidence of 13.7 % for PDWA with FA and an increased BC risk of 3.9 for FA with PDWA. In contrast, AH was seen with 2.2 % of all FA but was relatively more common with complex FA (6.0 %) than with simple FA (1.6 %). The frequency of atypical ductal hyperplasia (1.2 %) was somewhat lower in the study by Kuijper et al. [1] than in the study by Dupont et al. [2] (1.7 %). In the present study, the elevated risk for women with FA was not significantly different from that for women without FA (RR 1.51; 95 % CI 1.40-1.63). These findings suggest that the elevated risk for women with FA is similar to the overall BBD cohort risk rather than specific for the presence of the FA.
The study by Dupont et al. [2] reported risk association according to the location of the proliferative diseasewithin the FA or outside the FA. In our study, PDWA was associated with a slightly increased risk irrespective of whether it was present within the FA or outside the FA. The presence of AH within the FA was associated with an elevated risk, but the number of patients was small (RR 6.03; 95 % CI 2.21-13.12). Hence, our study suggests that the location of the PDWA or AH within the FA or outside the FA did not influence BC risk (Table 3) . Once again, these data suggest that the risk of BC in women with FA is driven mostly by the histologic features present in association with the FA, such as PDWA or AH.
In studying the association with other known risk factors for BC, we noted that the association of involution and risk in women with FA (RR 1.72; 95 % CI 1.27-2.28 for no involution and RR 0.80; 95 % CI 0.41-1.40 for complete involution; P = .03) was similar to the association for women with BBD overall [6] . Although there was no significant association between family history of BC and BC risk for women with FA (P = .08), women with a strong family history of BC had higher risk than those with no family history. In summary, the BC risk for the three categories of BBD in this cohort of women with FA was similar to the risk of women with BBD overall, suggesting that the elevated risk in this population was likely reflecting the underlying risk associated with BBD rather than with the FA itself.
Dupont et al. [2] reported elevated BC risk for women with complex FA. When we assessed the 4 histologic components of FA for associations with BC risk in the present study, none of the components of complex FA (cysts [3 mm, sclerosing adenosis, epithelial calcifications, or papillary apocrine changes) was significantly associated with BC risk (Table 4) . However, the presence of two or more of these components increased the risk of BC compared to only one factor (P = .007). BC risk was noted to be slightly higher for women with complex FA and PDWA as well as for those with complex FA and AH, but the difference was not significant (P = .17) ( Table 2) . This is likely because complex FA includes the histologic findings of PDWA, such as sclerosing adenosis, and the reported increased risk with complex FA reflects the risk associated with PDWA. As confirmed by a prior study from our group, sclerosing adenosis was found to be an independent risk marker for BC (SIR for BC, 2.10) [10] .
All 2136 FAs in the present study were excised, and none had concurrent BC. Prior reports showed the co-occurrence of in situ and invasive cancer ranging from 0.2 to 2 % [1, [11] [12] [13] , and Kuijper et al. [1] reported carcinoma in situ (both ductal carcinoma in situ and lobular carcinoma in situ) in 2.0 % of patients with FA. As a result, several authors have opted for conservative management of FA in younger women [1] . Another study showed that a large proportion of FAs in women younger than 20 years resolves spontaneously [14] . Studies have also reported that carcinoma in situ arising within FA is found mostly in women older than 35 years; therefore, removal of FAs in this age group has been suggested [1] . Although the present report did not specifically compare conservative management with excision of FA, the finding that malignancy within FA is rare suggests that a conservative approach with observation of FA is reasonable unless the mass increases in size over time.
Ciatto et al. [15] noted that the SIR for histologically confirmed FAs was slightly increased (SIR, 2.0; 95 % CI 1.4-2.7), whereas there was no apparent risk of non excised, clinically or mammographically detected FAs (SIR, 0.97; 95 % CI 0.7-1.4). Those investigators suggested that BC risk assessment may be biased, specifically when the analysis is limited to surgically excised FAs. All patients in the present study had surgical excision of their FAs, and we found a mild increase in BC risk for women with complex FA who presented with a lump compared with FA detected by mammogram, although the difference was not statistically significant ( Table 2 ). The reason for this is unclear. However, surgical excision by itself should not alter risk for FA since the lesion by itself is considered a nonproliferative histologic entity that is not associated with an increase in BC risk (RR for NP disease, 1.21; 95 % CI 1.08-1.34) ( Table 2 ).
The strength of the present study is its large BBD cohort exceeding 9000 women, including more than 2100 women with FA and women who were found to have FA in both the pre-mammographic era and the post-mammographic era. Samples were reviewed extensively by two experienced breast pathologists who used established criteria previously reported. The limitation of the current study is that all women had a surgical biopsy performed, and thus, we cannot comment on the current practice of clinical and radiologic observation alone, which is advised for mammographically detected small lesions found in some women.
Conclusions
The risk of BC for women with FA of the breast is similar to that for women with a diagnosis of BBD. Complex FA does not confer increased risk of BC beyond that of other established histologic features such as PDWA and AH. Therefore, the management of complex FA should be based on the associated histologic findings of BBD, such as PDWA or AH.
